JHS acquired the tech transfer for a COVID-19 liquid suspension vaccine product that was approved for use internationally, but not within the United States. This transfer was completed in less than half the time typically required. The challenge was developing a process to produce the vaccine in the US that did not compromise the sterility, or homogeneity, of the product.
Case Study: Adapting Equipment to Keep Pace with Demand
COVID-19 impacted the ability to acquire new or custom equipment in real time. Learn how JHS rapidly identified alternatives on a compressed timeline with a high level of collaboration.